Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Qiagen reported double-digit year-over-year sales growth in its core non-COVID-related product portfolio on Monday afternoon, prompting the company to raise its full-year guidance.

Cepheid said Monday it secured CE-IVD marking for its group B Streptococcus assay, Xpert Xpress GBS, and will start selling the test in Europe this month.

As a leading enterprise in China's in vitro diagnostic industry, Autobio Diagnostics CO.,Ltd. has continued to maintain a steady growth trend.

Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL.

For its first full quarter following a business combination, QuidelOrtho after the close of the market on Wednesday reported third-quarter revenues of $783.8 million, an increase of 54% compared to $509.8 million in Q3 2021 and in line with preliminary estimates announced in October.

Snibe announced its 2022 Q3 report, the company achieved operating revenue of RMB 880 million, up 31.67% year-on-year; net profit attributable to shareholders of the listed company was RMB 355 million, up 49.72% year-on-year.

Bruker reported before the open of markets on Thursday that revenues in the third quarter rose 5 percent year over year.

Twist Bioscience said on Tuesday that it has inked a partnership with Illumina to produce the co-branded Twist Bioscience for Illumina Exome 2.0 Plus panel for disease research.

In the evening of October 24, Beijing Hotgen Biotech Co., Ltd. (stock code: 688068) released its third quarter report for 2022. In the third quarter, Hotgen 's revenue and net profit continued to jump, achieving CNY 963 million revenue with a year-on-year increase of 391.95%

Veracyte reported after close of market Wednesday that its third quarter revenues increased 25 percent year over year, beating Wall Street estimates and prompting the firm to increase its full-year revenue guidance.